Welcome to our dedicated page for Ifabric news (Ticker: IFABF), a resource for investors and traders seeking the latest updates and insights on Ifabric stock.
iFabric Corp. (OTCQX: IFABF, TSX: IFA) is active in performance apparel, advanced textiles, and fabric treatments, and its news flow reflects this focus. Through subsidiaries Intelligent Fabric Technologies (North America) Inc. (IFTNA) and Coconut Grove Pads Inc., the company announces developments in antimicrobial technologies, durable water repellents, intimate apparel, and performance-driven finished products.
News updates for iFabric often highlight technology deployments and brand partnerships. Recent releases describe license agreements and product launches involving Doctor’s Choice scrubs and medical apparel, Roots branded footwear at a Canadian wholesale club retailer, Verzus All Apparel programs, TUMI travel products featuring PROTX2, Marks & Spencer’s Autograph collections in the UK and EU, and functional bedding in collaboration with The Lad Collective.
Investors and observers can use the IFABF news stream to follow clinical validation milestones, such as the publication of a clinical trial in the Journal of Hospital Infection demonstrating statistically significant reductions in bacterial loads on PROTX2 and ecoPEL treated scrubs. Other updates cover financing and capital resources, including trade finance facilities intended to support growth and manage foreign exchange risk, as described by the company.
Coverage also includes new product category expansions for IFTNA’s technology platforms, such as moves into footwear and bedding, as well as the rollout of performance apparel brands through major retailers. For a concise view of how iFabric’s textile technologies are being adopted across apparel, healthcare, travel, and home categories, the IFABF news page aggregates these announcements in one place.
iFabric Corp (OTCQX:IFABF) has announced that its subsidiary, Intelligent Fabric Technologies North America (IFTNA), has signed a significant licensing agreement with Mercury Athletics LLC to develop next-generation medical apparel under the Doctor's Choice® brand.
The collaboration will incorporate IFTNA's textile technologies, particularly PROTX2®, into healthcare scrubs and apparel. The partnership builds on Doctor's Choice's established reputation in diabetic and compression socks, expanding into the healthcare apparel sector. The new product line will be supported by IFTNA's peer-reviewed clinical trial published in the Journal of Hospital Infection in 2025.
iFabric Corp (OTCQX:IFABF) has renewed its license agreement with TUMI through its subsidiary Intelligent Fabric Technologies North America (IFTNA). The five-year extension continues the integration of IFTNA's PROTX2® antimicrobial technology across select TUMI products.
The renewed partnership will maintain PROTX2 implementation in TUMI's premium product lines, including the 19 Degree Polycarbonate carry-on linings, Travel Kits, Toiletry Kits, Laundry Bags, and select items within the Alpha Bravo, Alpha, Arrive' and McLaren collections.
iFabric Corp (OTCQX:IFABF) announced the expansion of its PROTX2 technology into the United Kingdom and European Union markets, marking a significant strategic expansion beyond North America. The company has secured a notable partnership with Marks & Spencer, which will incorporate PROTX2 technology into select items within its Autograph collections.
The PROTX2 brand mark will be prominently featured on merchandise hang tags both in-store and online, increasing brand visibility in these new regional markets. The company's Intelligent Fabric Technologies Division will support production programs incorporating PROTX2 technology in both the EU and UK regions.
iFabric Corp (OTCQX:IFABF) has announced the publication of groundbreaking clinical trial results in the Journal of Hospital Infection, demonstrating the effectiveness of their PROTX2® and ecoPEL™ antimicrobial technologies in healthcare settings.
The trial, conducted at MemorialCare Saddleback Medical Center, is the first successful antimicrobial textile trial to show statistically significant bacterial load reductions on scrubs in a real-world healthcare environment. The study validates that scrubs treated with PROTX2® and PROTX2® combined with ecoPEL™ significantly reduce surface bacterial contamination compared to untreated scrubs.
PROTX2® is EPA-registered and available for use throughout the United States, positioning IFTNA as a leader in healthcare-associated infection prevention solutions.
iFabric Corp (OTCQX:IFABF) reported its Q2 and H1 2025 financial results, with Q2 revenues remaining flat at $5.8 million compared to 2024. The company's H1 2025 revenues increased by 5% to $12.9 million. Q2 gross profit margin decreased to 37% from 42% in 2024, primarily due to $350,000 in brand advertising contributions.
The Intimate Apparel Division showed growth with a 10% revenue increase, while the Intelligent Fabrics Division saw a 7% decrease. The company reported a Q2 2025 net loss of $190,103 ($0.006 per share) compared to net earnings of $56,103 in 2024. Working capital remained strong at $19.2 million, with an unused $12 million credit facility available for future growth.
iFabric (OTCQX:IFABF) held its 2025 Annual General Meeting with approximately 65% shareholder participation, representing 19.5 million shares. All proposed matters received majority approval. The election of directors saw overwhelming support, with all six nominees receiving over 98.85% approval.
Shareholders also approved the appointment of BDO Canada LLP as auditors and fixed the number of directors at six. Notable directors Hylton Karon and Richard Macary received 99.86% and 99.94% of votes in favor, respectively.
iFabric Corp (IFABF) reported record Q1 2025 revenues of $7.08 million, a 5% increase from Q1 2024. The Intelligent Fabrics Division saw a 25% revenue increase to $5.82 million, while the Intimate Apparel Division experienced a 40% decrease to $1.25 million. Gross profit margins declined to 39% from 44%, resulting in a net earnings decrease to $88,458 ($0.003 per share) from $550,596 ($0.018 per share) in Q1 2024.
The company faces increased U.S. tariffs on Chinese imports (30%, up 10%), affecting 23% of total revenue. Cash position strengthened to $5.64 million, and the company expanded its bank operating line to $12 million. Management anticipates continued momentum and new product segments launch later in 2025, despite regulatory costs and ongoing leaching study expenses for Protx2.
iFabric Corp (IFABF) has announced two significant financial developments: First, the acquisition of the remaining 25% stake in its Markham, Ontario warehouse property subsidiary through a CDN$3.7 million mortgage financing from BMO. This financing will also be used to repay existing secured and minority shareholder loans.
Second, the company has secured a new banking agreement with BMO that increases its revolving operating credit facility from $6.75 million to $12 million. The facility, currently unutilized, is secured by company assets including a mortgage on the Markham property, which was recently valued at approximately $12 million.
iFabric Corp (IFABF) reported record financial results for Q4 and full year 2024. Q4 revenues reached a record $10.5 million, up 55% year-over-year, driven by new apparel programs. The company achieved Q4 gross profit of $4.17 million (40% margin) and Adjusted EBITDA of $1.9 million, a 636% increase.
For full-year 2024, revenues totaled $27.3 million, with the Intelligent Fabrics division growing 25% and Intimate Apparel division up 11% on a proportionate basis. Net earnings were $1.63 million ($0.054 per share) compared to a loss in 2023. Working capital improved to $19.6 million, with cash position strengthening to $2.06 million.
The company maintains a strong financial position with an unutilized $6.75 million bank operating line and expects continued double-digit sales growth in 2025, supported by new product categories and strong baseline sales from core programs.